NYSE:NVO Novo Nordisk A/S (NVO) Stock Price, News & Analysis $38.78 -0.44 (-1.13%) Closing price 10/16/2026 03:59 PM EasternExtended Trading$38.76 -0.02 (-0.04%) As of 10/16/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Novo Nordisk A/S Stock (NYSE:NVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novo Nordisk A/S alerts:Sign Up Key Stats Today's Range$38.67▼$39.4050-Day Range$37.31▼$48.6552-Week Range$35.12▼$64.16Volume10.80 million shsAverage Volume15.41 million shsMarket Capitalization$173.13 billionP/E Ratio9.66Dividend Yield2.11%Price Target$59.44Consensus RatingHold Company Overview Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care. Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products. The company also develops treatments for rare blood disorders, including hemophilia, and hormone-related conditions such as growth disorders. The company traces its history to the development of insulin production in Denmark during the 1920s. Novo Nordisk was formed in 1989 through the merger of Nordisk Gentofte and Novo Industri. Its products are marketed internationally, with operations and commercial activities serving patients and health care providers across numerous regions, including North America, Europe, Asia and other global markets.AI Generated. May Contain Errors. Read More Novo Nordisk A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreNVO MarketRank™: 3.95587650722 of 5 starsNovo Nordisk A/S scored higher than 79% of companies evaluated by MarketBeat, and ranked 90th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingNovo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 5 buy ratings, 16 hold ratings, and 5 sell ratings.Upside PotentialNovo Nordisk A/S has a consensus price target of $59.44, representing about 53.3% upside from its current price of $38.78.Amount of Analyst CoverageNovo Nordisk A/S has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Novo Nordisk A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Novo Nordisk A/S are expected to remain at $3.42 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novo Nordisk A/S is 9.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Novo Nordisk A/S is 9.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.22.Price to Earnings Growth RatioNovo Nordisk A/S has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovo Nordisk A/S has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novo Nordisk A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.71% of the float of Novo Nordisk A/S has been sold short.Short Interest Ratio / Days to CoverNovo Nordisk A/S has a short interest ratio ("days to cover") of 1.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novo Nordisk A/S has recently increased by 20.06%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovo Nordisk A/S pays a meaningful dividend of 2.08%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovo Nordisk A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novo Nordisk A/S is 19.80%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 23.68% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.Read more about Novo Nordisk A/S's dividend. News and Social Media2.8 / 5News Sentiment0.51 News SentimentNovo Nordisk A/S has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Novo Nordisk A/S this week, compared to 7 articles on an average week.Search InterestOnly 62 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat Follows31 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 182% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Novo Nordisk A/S is held by insiders.Percentage Held by Institutions11.54% of the stock of Novo Nordisk A/S is held by institutions.Read more about Novo Nordisk A/S's insider trading history. Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVO Stock News HeadlinesIs Novo Nordisk (CPSE:NOVO B) Cheap After Lillys EMA Win Raised GLP 1 Pressure?2 hours ago | finance.yahoo.comIs Novo Nordisk (CPSE:NOVO B) Facing A Bigger Threat In Europe?October 18 at 1:26 PM | finance.yahoo.comBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle is set to begin by October 20. Brown has built a new model portfolio featuring five AI plays tied to this pattern, which he says has repeated with a track record of success in the past. He notes this cycle unfolds outside the traditional stock market, combined with the ongoing AI boom.October 18 at 1:00 AM | Brownstone Research (Ad)Novo Nordisk A/SOctober 17 at 1:03 PM | 247wallst.comNovo Nordisk and Eli Lilly Just Got Some Fantastic NewsOctober 16 at 11:32 AM | fool.comOnly 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI (NVO)Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.October 15 at 5:43 PM | marketbeat.comViking's Obesity Edge May Be Staying Power, Not Weight Loss (NVO)Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.September 23, 2026 | marketbeat.comEli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.September 23, 2026 | marketbeat.comSee More Headlines NVO Stock Analysis - Frequently Asked Questions How have NVO shares performed this year? Novo Nordisk A/S's stock was trading at $50.88 at the start of the year. Since then, NVO stock has decreased by 23.8% and is now trading at $38.7760. How were Novo Nordisk A/S's earnings last quarter? Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Tuesday, June, 30th. The company reported $0.94 EPS for the quarter. The company earned $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a trailing twelve-month return on equity of 58.61%. When did Novo Nordisk A/S's stock split? Novo Nordisk A/S's stock split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were distributed to shareholders after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Novo Nordisk A/S have any subsidiaries? Novo Nordisk A/S subsidiaries include Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others. Who are Novo Nordisk A/S's major shareholders? Top institutional shareholders of Novo Nordisk A/S include Euro Pacific Asset Management LLC (0.01%), Cantor Fitzgerald Investment Advisors L.P. (0.01%), Penbrook Management LLC (0.01%) and Martin Capital Partners LLC. View institutional ownership trends. How do I buy shares of Novo Nordisk A/S? Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novo Nordisk A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Eli Lilly and Company (LLY), Tesla (TSLA), Broadcom (AVGO), Palantir Technologies (PLTR) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings6/30/2026Record date for 8/25 Dividend8/17/2026Ex-Dividend for 8/25 Dividend8/17/2026Dividend Payable8/25/2026Today10/18/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, NVO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NVO CIK353278 Webwww.novonordisk.com Phone(454) 444-8888Fax45-4449-0555Employees68,794Year Founded1923Price Target and Rating Average Price Target for Novo Nordisk A/S$59.44 High Price Target$175.00 Low Price Target$38.00 Potential Upside/Downside+53.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$4.09 Trailing P/E Ratio9.48 Forward P/E Ratio11.34 P/E Growth1.32Net Income$15.51 billion Net Margins35.36% Pretax Margin45.31% Return on Equity58.61% Return on Assets20.91% Debt Debt-to-Equity Ratio0.55 Current Ratio0.87 Quick Ratio0.66 Sales & Book Value Annual Sales$329.43 billion Price / Sales0.53 Cash Flow$4.68 per share Price / Cash Flow8.28 Book Value$6.58 per share Price / Book5.89Miscellaneous Outstanding Shares4,465,000,000Free Float4,461,875,000Market Cap$173.13 billion OptionableOptionable Beta0.76 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NYSE:NVO) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour download link expires soonThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Nordisk A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Novo Nordisk A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVO Stock Alerts